Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.116.178145DOI Listing

Publication Analysis

Top Keywords

reply somatostatin
4
somatostatin receptor-targeted
4
receptor-targeted radiopeptide
4
radiopeptide therapy
4
therapy patients
4
patients progressive
4
progressive unresectable
4
unresectable meningioma
4
reply
1
receptor-targeted
1

Similar Publications

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3-line treatment.

World J Gastroenterol

March 2021

Medical Oncology Department, The Ramón y Cajal Health Research Institute, Alcalá University, University Hospital Ramon y Cajal, Madrid 28034, Spain.

Background: Somatostatin analogues are an established first-line therapy for well differentiated small bowel neuroendocrine tumours (Wd-SBNETs), while and peptide receptor radionuclide therapy (PRRT) is frequently used as a second-line therapy. Adequate treatment selection of third-line treatment remains challenging due to the limited prospective data currently available on the best therapeutic sequence.

Aim: To understand current practice and rationale for decision-making by physicians in the 3-line setting by building an online survey.

View Article and Find Full Text PDF

Shrinkage of pituitary adenomas with pasireotide - Authors' reply.

Lancet Diabetes Endocrinol

July 2019

Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!